&lt;p&gt;Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease&lt;/p&gt;

Guarnotta, Valentina; Prinzi, Antonio; Pitrone, Maria; Pizzolanti, Giuseppe; Giordano, Carla

doi:10.2147/dmso.s249090

Cited by 16 publications

(13 citation statements)

References 57 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin D, also known as cholecalciferol, is first formed in the skin by the photolysis of 7-dehydrocholesterol and after hydroxylated in the liver to 25 Cushing's disease (CD) is characterized by a cortisol excess due to autonomous pituitary ACTH secretion. Patients with CD show many comorbidities such as cardiovascular disease, metabolic disease, diabetes mellitus, metabolic syndrome, dyslipidemia, obesity, osteoporosis/osteopenia and infections that contribute to increasing the mortality risk for these patients [5][6][7][8][9][10][11]. Indeed, GCs are key regulators of intermediary metabolism promoting hepatic gluconeogenesis and glycogenosis and on lipid metabolism favouring the deposition of fat to the upper trunk and the face [12].…”

Section: Introductionmentioning

confidence: 99%

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation

2022

Self Cite

View full text Add to dashboard Cite

Background: The primary objective of the study was to assess serum 25-hydroxyvitamin D [25(OH)D] values in patients with Cushing’s disease (CD), compared to controls. The secondary objective was to assess the response to a load of 150,000 U of cholecalciferol. Methods: In 50 patients with active CD and 48 controls, we evaluated the anthropometric and biochemical parameters, including insulin sensitivity estimation by the homeostatic model of insulin resistance, Matsuda Index and oral disposition index at baseline and in patients with CD also after 6 weeks of cholecalciferol supplementation. Results: At baseline, patients with CD showed a higher frequency of hypovitaminosis deficiency (p = 0.001) and lower serum 25(OH)D (p < 0.001) than the controls. Six weeks after cholecalciferol treatment, patients with CD had increased serum calcium (p = 0.017), 25(OH)D (p < 0.001), ISI-Matsuda (p = 0.035), oral disposition index (p = 0.045) and decreased serum PTH (p = 0.004) and total cholesterol (p = 0.017) values than at baseline. Multivariate analysis showed that mean urinary free cortisol (mUFC) was independently negatively correlated with serum 25(OH)D in CD. Conclusions: Serum 25(OH)D levels are lower in patients with CD compared to the controls. Vitamin D deficiency is correlated with mUFC and values of mUFC > 240 nmol/24 h are associated with hypovitaminosis D. Cholecalciferol supplementation had a positive impact on insulin sensitivity and lipids.

show abstract

Section: Introductionmentioning

confidence: 99%

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation

2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In fact, 40–70% of patients with CD report muscle weakness especially in the proximal muscles of the lower extremities [ 70 , 71 ]. Therefore, these patients have difficulty getting up from a squatting position or climbing stairs, whereas they have less difficulty running or walking [ 72 , 73 ]. Moreover, patients with CD, develop sarcopenia, which is generally associated with obesity and osteoporosis, leading to a condition called osteosarcopenic obesity [ 73 ].…”

Section: Irisin In Cushing’s Disease (Cd)mentioning

confidence: 99%

“…Excess cortisol could affect circulating irisin levels, especially since skeletal muscle, the main source of irisin, is one of the target organs of cortisol. A recent study evaluated circulating irisin levels in patients with active, controlled Cushing’s disease [ 73 ]. Guarnotta et al, observed that circulating irisin levels were lower in patients with CD before and after the correction of hypercortisolism compared with controls [ 73 ].…”

Section: Irisin In Cushing’s Disease (Cd)mentioning

confidence: 99%

“…A recent study evaluated circulating irisin levels in patients with active, controlled Cushing’s disease [ 73 ]. Guarnotta et al, observed that circulating irisin levels were lower in patients with CD before and after the correction of hypercortisolism compared with controls [ 73 ]. Given the role of irisin as a player in the bone, muscle, and adipose tissue axis, further studies will certainly be relevant to understand whether this molecule represents a marker for the diagnosis of osteosarcopenia and central obesity in patients with CD.…”

Section: Irisin In Cushing’s Disease (Cd)mentioning

confidence: 99%

See 1 more Smart Citation

Irisin and Secondary Osteoporosis in Humans

Zerlotin

Oranger

Pignataro

et al. 2022

IJMS

View full text Add to dashboard Cite

Irisin is a peptide secreted by skeletal muscle following exercise that plays an important role in bone metabolism. Numerous experiments in vitro and in mouse models have shown that the administration of recombinant irisin promotes osteogenesis, protects osteocytes from dexamethasone-induced apoptosis, prevents disuse-induced loss of bone and muscle mass, and accelerates fracture healing. Although some aspects still need to be elucidated, such as the dose- and frequency-dependent effects of irisin in cell cultures and mouse models, ample clinical evidence is emerging to support its physiological relevance on bone in humans. A reduction in serum irisin levels, associated with an increased risk of osteoporosis and bone fractures, was observed in postmenopausal women and in both men and women during aging, Recently, cohort studies of subjects with secondary osteoporosis showed that these patients have lower circulating levels of irisin, suggesting that this myokine could be a novel marker to monitor bone quality in this disease. Although there are still few studies, this review discusses the emerging data that are highlighting the involvement of irisin in some diseases that cause secondary osteoporosis.

show abstract

“…Decreased irisin concentrations are associated with muscle pathology. Whereas acute muscle injury may cause increased irisin levels (48), several studies suggest a decrease in circulating irisin in chronic myopathies such as myotonic dystrophy (49), sarcopenia (50), and Cushing disease (51) or hypothyroidism (52)-associated myopathies. Until now, little attention has been paid to muscle disorders in acromegaly, but some research points toward the existence of myopathy connected with this disease, clinically manifesting as muscle weakness (53)(54)(55), diplopia (56), and muscle atrophy (55) with inhomogeneous pattern in muscle biopsy examination (57)(58)(59) and occasionally elevated creatine kinase or myopathic electromyography record (57,60).…”

Section: Irisinmentioning

confidence: 99%

Myokines in Acromegaly: An Altered Irisin Profile

et al. 2021

View full text Add to dashboard Cite

IntroductionThe muscle is an endocrine organ controlling metabolic homeostasis. Irisin and myostatin are key myokines mediating this process. Acromegaly is a chronic disease with a wide spectrum of complications, including metabolic disturbances.PurposeTo examine the influence of acromegaly on irisin and myostatin secretion and their contribution to metabolic profile and body composition.Materials and MethodsIn 43 patients with acromegaly and 60 controls, serum levels of irisin, myostatin, growth hormone (GH), insulin-like growth factor 1 (IGF-1), parameters of glucose, and lipid metabolism were determined. Body composition was assessed with dual-energy x-ray absorptiometry.ResultsThe irisin concentration was significantly lower in patients with acromegaly compared to controls (3.91 vs. 5.09 μg/ml, p = 0.006). There were no correlations between irisin and GH/IGF-1 levels. In the study group, irisin was negatively correlated with fasting insulin (r = −0.367; p = 0.042), HOMA-IR (r = −0.510; p = 0.011), and atherogenic factors: Castelli I (r = −0.416; p = 0.005), Castelli II (r = −0.400; p = 0.001), and atherogenic coefficient (AC) (r = −0.417; p = 0.05). Irisin and myostatin concentrations were also lower in acromegalics with insulin resistance than without (2.80 vs. 4.18 μg/ml, p = 0.047; 81.46 vs. 429.58 ng/L, p = 0.018, respectively). There were no differences between study group and controls in myostatin concentration. Myostatin levels negatively correlated with GH (r = −0.306; p = 0.049), HOMA-IR (r = −0.046; p = 0.411), and insulin levels (r = −0.429; p = 0.016).ConclusionsDecreased irisin concentrations in acromegaly may suggest impaired hormonal muscle function contributing to metabolic complications in this disorder. However, learning more about the association between myostatin and GH in acromegaly requires further studies. Nevertheless, it appears that myostatin is not critical for muscle mass regulation in acromegaly.

show abstract

<p>Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease</p>

Cited by 16 publications

References 57 publications

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation

Irisin and Secondary Osteoporosis in Humans

Myokines in Acromegaly: An Altered Irisin Profile

Contact Info

Product

Resources

About